Clareo Health | A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The A7471031 study was terminated on May 2, 2012. The decision for unplanned study termination was triggered by feasibility of further conduct of this trial as only 22 of the protocol-specified 75 patients were enrolled since the study initiated in February 2010. Based on this low accrual rate it was determined that the study was highly unlikely to complete accrual and provide meaningful data. The discontinuation of the study is not due to any safety issue.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Radiographs consistent with lung cancer for which resection is indicated upon histologic confirmation of non-small cell lung cancer.
Patient willing to take PF-00299804 for 5 to 11 days and provide blood and tissue specimens as required in the study.
You may not be if
Prior or concurrent systemic anticancer therapy for cancer (immunotherapy, hormonotherapy, biological therapy, or chemotherapy) less than one year from time of consent.
Prior or concurrent radiation therapy to tumor at site of planned resection.
